SELF-ASSEMBLED NANOSTRUCTURES OF ELASTIN-AND RESILIN-BASED BLOCK COPOLYPEPTIDES WITH STIMULI RESPONSIVENESS AND RESILIENCE FOR DRUG DELIVERY SYSTEM, TISSUE ENGINEERING AND REGENERATIVE MEDICINE AND METHODS OF PREPARING THE SAME
20200354416 ยท 2020-11-12
Assignee
Inventors
- Dong Woo Lim (Ansan-si, KR)
- Aamna Basheer (Ansan-si, KR)
- Jae Sang Lee (Ansan-si, KR)
- Min Jung Kang (Bucheon-si, KR)
Cpc classification
C08J2389/00
CHEMISTRY; METALLURGY
C07K14/78
CHEMISTRY; METALLURGY
A61K47/42
HUMAN NECESSITIES
A61K9/06
HUMAN NECESSITIES
A61K38/39
HUMAN NECESSITIES
A61L27/227
HUMAN NECESSITIES
C08L89/00
CHEMISTRY; METALLURGY
International classification
A61K47/42
HUMAN NECESSITIES
A61L27/22
HUMAN NECESSITIES
C07K14/78
CHEMISTRY; METALLURGY
Abstract
The present disclosure relates to a self-assembled nanostructure of an elastin- and resilin-based block copolypeptide with stimuli responsiveness and resilience for drug delivery, tissue engineering and regenerative medicine, a method for preparing the same and application thereof. The diblock polypeptide reversibly forms a self-assembled micelle structure in response to temperature stimuli and a hydrogel prepared using the triblock polypeptide undergoes reversible sol-gel or gel-sol transition in response to temperature stimuli and exhibits enhanced mechanical strength due to chemical crosslinkages between tyrosine residues. With such superior properties, the diblock/triblock polypeptide of the present disclosure can be used for drug delivery systems, scaffolds for tissue engineering and kits for tissue or organ regeneration.
Claims
1. A resilin-based polypeptide (RBP) exhibiting a phase transition behavior, which consists of an amino acid sequence represented by SEQ ID NO:44.
2. The resilin-based polypeptide (RBP) according to claim 1, wherein a gene sequence encoding the resilin-based polypeptide is SEQ ID NO:42.
3. A diblock polypeptide with stimuli responsiveness, represented by Formula 1, which consists of: a resilin-based polypeptide block; and a polypeptide block exhibiting a phase transition behavior, which is connected to one end of the resilin-based polypeptide block:
[hydrophobic EBP].sub.m-[RBP].sub.n[Formula 1] wherein n or m is independently an integer 1 or greater, the [RBP] is a resilin-based polypeptide block consisting of an amino acid sequence represented by SEQ ID NO:44 and the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO:1, a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO:2 or an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO:3 (wherein X is any natural or artificial amino acid except proline which is selected as the pentapeptide VPGXG, VPAXG or IPAXG is repeated).
4. The diblock polypeptide with stimuli responsiveness according to claim 3, wherein the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO:1, wherein each X of the repeating pentapeptide consists of: A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:23]; K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:25]; D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:27]; E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:29]; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:31].
5. The diblock polypeptide with stimuli responsiveness according to claim 3, wherein the [hydrophobic EBP] is a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO:2, wherein each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:32]; K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:33]; D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:34]; K (Lys) and F (Phe) at a ratio of 3:3 [SEQ ID NO:35]; D (Asp) and F (Phe) at a ratio of 3:3 [SEQ ID NO:36]; H (His), A (Ala) and I (Ile) at a ratio of 3:2:1 [SEQ ID NO:37]; H (His) and G (Gly) at a ratio of 5:1 [SEQ ID NO:38]; or G (Gly), C(Cys) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:39].
6. The diblock polypeptide with stimuli responsiveness according to claim 3, wherein the [hydrophobic EBP] is an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO:3, wherein each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:4:1 [SEQ ID NO:40]; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:41].
7. The diblock polypeptide with stimuli responsiveness according to claim 3, wherein the diblock polypeptide undergoes dynamic change wherein a [RBP] block core-[hydrophobic EBP] block shell micelle structure is formed through self-assembly at or below the lower critical solution temperature of the [hydrophobic EBP], an aggregate is formed at or above the lower critical solution temperature of the [hydrophobic EBP] and a [hydrophobic EBP] block core-[RBP] block shell micelle structure is formed at or above the upper critical solution temperature of the [RBP].
8. The diblock polypeptide with stimuli responsiveness according to claim 7, wherein the dynamic change is reversible in response to temperature.
9. A drug delivery composition comprising the diblock polypeptide according to claim 3.
10. A triblock polypeptide with stimuli responsiveness, represented by Formula 2 which consists of: a resilin-based polypeptide block; and polypeptide blocks exhibiting a phase transition behavior, which are connected to both ends of the resilin-based polypeptide block:
[hydrophobic EBP].sub.m-[RBP].sub.n-[hydrophobic EBP].sub.m[Formula 2] wherein n or m is independently an integer 1 or greater, the [RBP] is a resilin-based polypeptide block comprising an amino acid sequence represented by SEQ ID NO:44 and the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO:1, a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO:2 or an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO:3 (wherein X is any natural or artificial amino acid except proline which is selected as the pentapeptide VPGXG, VPAXG or IPAXG is repeated).
11. The triblock polypeptide with stimuli responsiveness according to claim 10, wherein the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO:1, wherein each X of the repeating pentapeptide consists of: A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:23]; K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:25]; D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:27]; E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1 [SEQ ID NO:29]; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:31].
12. The triblock polypeptide with stimuli responsiveness according to claim 10, wherein the [hydrophobic EBP] is a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO:2, wherein each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:32]; K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:33]; D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:34]; K (Lys) and F (Phe) at a ratio of 3:3 [SEQ ID NO:35]; D (Asp) and F (Phe) at a ratio of 3:3 [SEQ ID NO:36]; H (His), A (Ala) and I (Ile) at a ratio of 3:2:1 [SEQ ID NO:37]; H (His) and G (Gly) at a ratio of 5:1 [SEQ ID NO:38]; or G (Gly), C(Cys) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:39].
13. The triblock polypeptide with stimuli responsiveness according to claim 10, wherein the [hydrophobic EBP] is an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO:3, wherein each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:4:1 [SEQ ID NO:40]; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2 [SEQ ID NO:41].
14. A hydrogel prepared by a process comprising: a step of applying temperature stimuli to the triblock polypeptide according claim 11; and a step of forming crosslinkages between the triblock polypeptide in response to the temperature stimuli.
15. The hydrogel according to claim 14, wherein the crosslinkages are physical crosslinkages formed between the [hydrophobic EBP] block at or above the lower critical solution temperature of the [hydrophobic EBP].
16. The hydrogel according to claim 14, wherein the hydrogel undergoes reversible sol-gel or gel-sol transition in response to temperature stimuli.
17. The hydrogel according to claim 14, wherein the hydrogel has enhanced mechanical strength due to chemical crosslinkages between the tyrosine residues of the resilin-based polypeptide block.
18. A composition for drug delivery comprising the hydrogel according to claim 14.
19. A scaffold for tissue engineering comprising the hydrogel according to claim 14.
20. A kit for tissue or organ regeneration comprising the hydrogel according to claim 14.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
DETAILED DESCRIPTION OF THE INVENTION
[0099] Hereinafter, specific examples are presented to help understanding the present disclosure. However, the following examples are given only to help better understanding of the present disclosure and the present disclosure is not limited by the examples.
EXAMPLES
Example 1. Materials
[0100] The pET-21a vector and BL21 (DE3) E. coli cells were obtained from Novagen Inc. (Madison, Wis., US). Top10 competent cells were obtained from Invitrogen (Carlsbad, Calif., US). Oligonucleotides were synthesized chemically at Cosmo Gene Tech (Seoul, South Korea). The FastAP thermosensitive alkaline phosphatase and restriction endonuclease including BamHI and XbaI were purchased from Fermentas (Ontario, Canada). Other restriction endonuclease including BseRI and AcuI and all other restriction enzymes were obtained from New England Biolabs (Ipswich, Mass., US). DNA miniprep, gel extraction and PCR purification kits were obtained from Geneall Biotechnology (Seoul, South Korea). Dyne Agarose High was obtained from Dyne Bio, Inc. (Seongnam, South Korea). All the Top10 cells were grown in TB DRY media obtained from MO Bio Laboratories, Inc. (Carlsbad. Calif., US). All the BL21 (DE3) cells were grown in CircleGrow media obtained from MP Biomedicals (Solon, Ohio, US). Ready Gel (Tris-HCl 2-20%) as a precast gel was purchased from Bio-Rad (Hercules, Calif., US). Phosphate-buffered saline (PBS, pH 7.4), ampicillin and polyethyleneimine (PEI) were obtained from Sigma-Aldrich (St Louis, Mo.).
Example 2. Notation for Different EBP Blocks and their Block Polypeptides
[0101] Different EBPs with a pentapeptide repeating unit, Val-Pro-(Gly or Ala)-X.sub.aa-Gly [VP(G or A)XG], where X.sub.aa can be any amino acid except Pro are named as follows. First, the pentapeptide repeat of Val-Pro-Ala-X.sub.aa-Gly (VPAXG) with plasticity is defined as an elastin-based polypeptide with plasticity (EBPP) while the pentapeptide repeat of Val-Pro-Gly-X.sub.aa-Gly (VPGXG) being called an elastin-based polypeptide with elasticity (EBPE). And, the pentapeptide repeat of Ile-Pro-Ala-X.sub.aa-Gly (IPAXG) wherein the first amino acid is substituted with Ile is defined as an elastin-based polypeptide with plasticity and substituted with Ile (EBPPI). Secondly, [X.sub.iY.sub.jZ.sub.k].sub.n represents that the bracketed capital letters are single letter amino acid codes of the guest residues, i.e. the amino acid at the fourth position (X.sub.aa or X) in the EBP pentapeptide, and their corresponding subscripts denote the ratio of that guest residue in the EBP monomer gene as the repeating unit. The subscript number n of [X.sub.iY.sub.jZ.sub.k].sub.n indicates the total repeating number of SEQ ID NO:1 [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG], SEQ ID NO:2 [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] or SEQ ID NO:3 [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] in the EBP. For example, EBPP[G.sub.1A.sub.3F.sub.2].sub.12 is an EBPP block that contains 12 repeats of SEQ ID NO:2 [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG], in which the ratio of Gly, Ala and Phe at the fourth guest residue position (X.sub.aa) is 1:3:2.
[0102] Two RBPs having different sequences are named as RBP[Dros].sub.n and RBP[m-Dros].sub.n, where n represents the number of repeating unit. Both sequences are derived from Drosophila exon 1 and the RBP repeating unit contains two repeating sequences of resilin. For RBP[Dros].sub.n, the repeating sequences are the same as reported in previous studies while, for RBP[m-Dros].sub.n, the two repeating sequences of resilin are combined with slight modifications to get the desired properties such as temperature responsiveness and high resilience. The EBPP-RBP diblock and triblock polypeptides are named by the composition of each block in square brackets with a hyphen between blocks such as EBPP[G.sub.1A.sub.3F.sub.2].sub.n-RBP[Dros/m-Dros].sub.n for a diblock and EBPP[G.sub.1A.sub.3F.sub.2].sub.n-RBP[Dros/m-Dros].sub.n-EBPP[G.sub.1A.sub.3F.sub.2].sub.n for a triblock.
Example 3. Preparation of Modified pET-21a Vector for Seamless Gene Cloning
[0103] As shown in
Example 4. Monomer Gene Synthesis and Oligomerization for RBP and EBP
[0104] The EBP sequences with a pentapeptide repeating unit, Val-Pro-(Gly or Ala)-X.sub.aa-Gly, where the fourth residues are varied at different molar ratios were designed at DNA level to optimize T.sub.t below the physiological temperature. The DNA and amino acid sequences of the EBPs with various pentapeptide repeating units are shown in Table 1 and Table 2, respectively.
TABLE-US-00001 TABLE1 GenesequencesofEBPlibraries EBP EBPE[A.sub.1G.sub.4I.sub.1] GTCCCAGGTGGAGGTGTACCCGGCGCGGGTGTCCCAGGTGGAGGT (SEQIDNO:4) GTACCTGGGGGTGGGGTCCCTGGTATTGGCGTACCTGGAGGCGGC EBPP[A.sub.1G.sub.4I.sub.1] GTTCCAGCTGGCGGTGTACCTGCTGCTGCTGTTCCGGCCGGTGGT (SEQIDNO:5) GTTCCGGCGGGCGGCGTGCCTGCAATAGGAGTTCCCGCTGGTGGC EBPE[K.sub.1G.sub.4I.sub.1] GTTCCGGGTGGTGGTGTTCCGGGTAAAGGTGTTCCGGGTGGTGGT (SEQIDNO:6) GTTCCGGGTGGTGGTGGTGTTCCGGGTATCGGTGTTCCGGGTGGC EBPP[K.sub.1G.sub.4I.sub.1] GTTCCGGCGGGTGGTGTTCCGGCGAAAGGTGTTCCGGCGGGTGGT (SEQIDNO:7) GTTCCGGCGGGTGGTGTTCCGGCGATCGGTGTTCCGGCGGGTGGC EBPE[D.sub.1G.sub.4I.sub.1] GTTCCGGGTGGTGGTGTTCCGGGTGATGGTGTTCCGGGTGGTGGT (SEQIDNO:8) GTTCCGGGTGGTGGTGGTGTTCCGGGTATCGGTGTTCCGGGTGGC EBPP[D.sub.1G.sub.4I.sub.1] GTTCCGGCGGGTGGTGTTCCGGCGGATGGTGTTCCGGCGGGTGGT (SEQIDNO:9) GTTCCGGCGGGTGGTGTTCCGGCGATCGGTGTTCCGGCGGGTGGC EBPE[E.sub.1G.sub.4I.sub.1] GTTCCGGGTGGTGGTGTTCCGGGTGAAGGTGTTCCGGGTGGTGGT (SEQIDNO:10) GTTCCGGGTGGTGGTGGTGTTCCGGGTATCGGTGTTCCGGGTGGC EEPP[E.sub.1G.sub.4I.sub.1] GTTCCGGCGGGTGGTGTTCCGGCGGAAGGTGTTCCGGCGGGTGGT (SEQIDNO:11) GTTCCGGCGGGTGGTGTTCCGGCGATCGGTGTTCCGGCGGGTGGC EBPE[G.sub.1A.sub.3F.sub.2] GTCCCGGGTGCGGGCGTGCCGGGATTTGGAGTTCCGGGTGCGGGT (SEQIDNO:12) GTTCCAGGCGGTGGTGTTCCGGGCGCGGGCGTGCCGGGCTTTGGC EBPP[G.sub.1A.sub.3F.sub.2] GTGCCGGCGGCGGGCGTTCCAGCCTTTGGTGTGCCAGCGGCGGGA (SEQIDNO:13) GTTCCGGCCGGTGGCGTGCCGGCAGCGGGCGTGCCGGCTTTTGGC EBPP[K.sub.1A.sub.3F.sub.2] GTGCCGGCGGCGGGCGTTCCAGCCTTTGGTGTGCCAGCGGCGGGA (SEQIDNO:14) GTTCCGGCCAAAGGCGTGCCGGCAGCGGGCGTGCCGGCTTTTGGC EBPP[D.sub.1A.sub.3F.sub.2] GTGCCGGCGGCGGGCGTTCCAGCCTTTGGTGTGCCAGCGGCGGGA (SEQIDNO:15) GTTCCGGCCGATGGCGTGCCGGCAGCGGGCGTGCCGGCTTTTGGC EBPP[K.sub.3F.sub.3] GTTCCAGCGTTTGGCGTGCCAGCGAAAGGTGTTCCGGCGTTTGGG (SEQIDNO:16) GTTCCCGCGAAAGGTGTGCCGGCCTTTGGTGTGCCGGCCAAAGGC EBPP[D.sub.3F.sub.3] GTTCCAGCGTTTGGCGTGCCAGCGGATGGTGTTCCGGCGTTTGGG (SEQIDNO:17) GTTCCCGCGGATGGTGTGCCGGCCTTTGGTGTGCCGGCCGATGGC EBPP[H.sub.3A.sub.3I.sub.1] GTGCCGGCGCATGGAGTTCCTGCCGCCGGTGTTCCTGCGCATGGT (SEQIDNO:18) GTACCGGCAATTGGCGTTCCGGCACATGGTGTGCCGGCCGCCGGC EBPP[H.sub.5G.sub.1] GTTCCGGCCGGAGGTGTACCGGCGCATGGTGTTCCGGCACATGGT (SEQIDNO:19) GTGCCGGCTCACGGTGTGCCTGCGCATGGCGTTCCTGCGCATGGC EBPP[G.sub.1C.sub.3F.sub.2] GTGCCGGCGTGCGGCGTTCCAGCCTTTGGTGTGCCAGCGTGCGGA (SEQIDNO:20) GTTCCGGCCGGTGGCGTGCCGGCATGCGGCGTGCCGGCTTTTGGC EBPPI[G.sub.1A.sub.4F.sub.1] ATTCCTGCAGCCGGTATCCCGGCCGGTGGCATTCCGGCAGCCGGC (SEQIDNO:21) ATTCCGGCCGCCGGCATCCCGGCATTTGGCATTCCTGCAGCAGGC EBPPI[G.sub.1A.sub.3F.sub.2] ATTCCGGCCGCAGGCATTCCTGCATTTGGTATTCCGGCGGCAGGC (SEQIDNO:22) ATTCCTGCCGGTGGCATCCCGGCAGCGGGCATTCCGGCCTTTGGC
TABLE-US-00002 TABLE2 AminoacidsequencesofEBPlibraries EBP EBPE[A.sub.1G.sub.4I.sub.1] VPGGG VPGAG VPGGG VPGGG VPGIG VPGGG (SEQIDNO:23) EBPP[A.sub.1G.sub.4I.sub.1] VPAGG VPAAG VPAGG VPAGG VPAIG VPAGG (SEQIDNO:24) EBPE[K.sub.1G.sub.4I.sub.1] VPGGG VPGKG VPGGG VPGGG VPGIG VPGGG (SEQIDNO:25) EBPP[K.sub.1G.sub.4I.sub.1] VPAGG VPAKG VPAGG VPAGG VPAIG VPAGG (SEQIDNO:26) EBPE[D.sub.1G.sub.4I.sub.1] VPGGG VPGDG VPGGG VPGGG VPGIG VPGGG (SEQIDNO:27) EBPP[D.sub.1G.sub.4I.sub.1] VPAGG VPADG VPAGG VPAGG VPAIG VPAGG (SEQIDNO:28) EBPE[E.sub.1G.sub.4I.sub.1] VPGGG VPGEG VPGGG VPGGG VPGIG VPGGG (SEQIDNO:29) EBPP[E.sub.1G.sub.4I.sub.1] VPAGG VPAEG VPAGG VPAGG VPAIG VPAGG (SEQIDNO:30) EBPE[G.sub.1A.sub.3F.sub.2] VPGAG VPGFG VPGAG VPGGG VPGAG VPGFG (SEQIDNO:31) EBPP[G.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQIDNO:32) EBPP[K.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQIDNO:33) EBPP[D.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQIDNO:34) EBPP[K.sub.3F.sub.3] VPAFG VPAKG VPAFG VPAKG VPAFG VPAKG (SEQIDNO:35) EBPP[D.sub.3F.sub.3] VPAFG VPADG VPAFG VPADG VPAFG VPADG (SEQIDNO:36) EBPP[H.sub.3A.sub.3I.sub.1] VPAHG VPAAG VPAHG VPAIG VPAHG VPAAG (SEQIDNO:37) EBPP[H.sub.5G.sub.1] VPAGG VPAHG VPAHG VPAHG VPAHG VPAHG (SEQIDNO:38) EBPP[G.sub.1C.sub.3F.sub.2] VPACG VPAFG VPACG VPAGG VPACG VPAFG (SEQIDNO:39) EBPPI[G.sub.1A.sub.4F.sub.1] IPAAG IPAGG IPAAG IPAAG IPAFG IPAAG (SEQIDNO:40) EBPPI[G.sub.1A.sub.3F.sub.2] IPAAG IPAFG IPAAG IPAGG IPAAG IPAFG (SEQIDNO:41)
[0105] In Table 1, SEQ ID NOS 4-11 may be classified as gene sequences for hydrophilic EBP blocks and SEQ ID NOS 12-22 may be classified as gene sequences for Phe- and His-containing hydrophobic EBP blocks. In Table 2, SEQ ID NOS 23-30 may be classified as hydrophilic and SEQ ID NOS 31-41 containing Phe and His may be classified as hydrophobic EBP blocks. That is to say, hydrophobicity is exhibited when the LOST of EBP is below the body temperature and hydrophilicity is exhibited when the LOST of EBP is above the body temperature. Therefore, the hydrophilicity and hydrophobicity of the EBP may be defined relatively with regard to bioengineering applications.
[0106] Different EBPs having the pentapeptide repeating unit Val-Pro-(Gly or Ala)-X.sub.aa-Gly [where X.sub.aa may be any amino acid except Pro] were designed at DNA level to have unique responsiveness to stimuli including temperature and pH. Both the EBP with plasticity (EBPP) having the Val-Pro-Ala-X.sub.aa-Gly pentapeptide repeats and the EBP with elasticity (EBPE) having the Val-Pro-Gly-X.sub.aa-Gly pentapeptide repeats were replicated to have the same guest residue composition and ratio. The gene and amino acid sequences of the EBPs with different pentapeptide repeating units are shown in Table 1 and Table 2, respectively. For example, EBPE[G.sub.1A.sub.3F.sub.2].sub.12 and EBPP[G.sub.1A.sub.3F.sub.2].sub.12 show not only almost the same molar mass and but also the same combination of the fourth residue of the EBP pentapeptide repeating unit. They have different mechanical properties due to the difference in the third amino acid residue (Ala or Gly) of the pentapeptide repeating unit. Positively and negatively charged EBPs were constructed by introducing charged amino acids such as Lys, Asp, Glu, His, etc. as guest residues. In addition, in order to investigate the effect of the first amino acid (Val or Ile) on temperature responsiveness and physical crosslinking of the triblock polypeptide, the first amino acid Val of the pentapeptide unit was substituted with Ile, i.e., Ile-Pro-Ala-X-Gly.
[0107] 50 L of each pair of oligonucleotides for encoding various EBPs at 2 M concentration in T4 DNA ligase buffer were annealed by heating at 95 C. for 2 minutes and then slowly cooled down to the room temperature over 3 hours. The resulting dsDNA products have nonpalindromic, 2 bp, 3 overhangs. A total of 4 g of the modified pET-21a(+)vector was digested with 15 U of BseRI in FastDigest buffer for 30 minutes at 37 C. The 5 ends were dephosphorylated with 10 U of CIP in NEB 3 buffer for 1 hour at 37 C. The restricted vector was purified using the PCR purification kit and was eluted in 40 L of distilled deionized water. The dsDNA was inserted into the linearized and modified pET-21a(+) vector by incubating 90 pmol of the annealed dsDNA and 30 pmol of the vector in T4 DNA ligase buffer containing T4 DNA ligase at 16 C. for 30 minutes. The ligated vector was introduced into chemically transformed Top10 competent cells, and then plated on SOC (Super Optimal Broth with catabolite repression) plates supplemented with 50 g/mL of ampicillin. The insert sequence was confirmed by DNA sequencing.
[0108] Two RBPs, RBP[Dros].sub.n and RBP[m-Dros].sub.n, were derived from Drosophila exon 1. The RBP[Dros].sub.n sequence was reported in previous studies with a repeating sequence of GGRPSDTYGAPGGGN. But, in the present disclosure, two sequences were combined in the repeating unit to have same molecular weight as RBP[m-Dros].sub.n. The RBP[m-Dros].sub.n was RBP[Dros].sub.n modified with two repeating sequences of GGRPSDSYGAPGGGN and GGRPSSSYGAPGQGN. The nucleotide and amino acid sequences of RBP[Dros].sub.1 and RBP[m-Dros].sub.1 are given in Table 3 and Table 4, respectively.
TABLE-US-00003 TABLE3 GenesequencesofRBPlibraries RBP RBP[m-Dros].sub.1 GGCGGCCGTCCGTCAGATTCTTATGGCGCACCGGGTGGGGGTAAT (SEQIDNO:42) GGCGGCCGTCCATCTTCGAGCTATGGCGCACCGGGCCAAGGTAAT RBP[Dros].sub.1 GGGGCGCCGGGTGGTGGCAACGGTGGTCGTCCGAGCGATACCTAC (SEQIDNO:43) GGGGCGCCGGGTGGTGGCAACGGTGGTCGTCCGAGCGATACCTAC
TABLE-US-00004 TABLE4 AminoacidsequencesofRBPlibraries RBP RBP[m-Dros].sub.1 GGRPSDSYGAPGGGNGGRPSSSYGAPGQGN (SEQIDNO:44) RBP[Dros].sub.1 GGRPSDTYGAPGGGNGGRPSDTYGAPGGGN (SEQIDNO:45)
[0109] As shown in
Example 5. Expression/Purification and Characterization of RBP
[0110] The RBP[Dros].sub.n and RBP[m-Dros].sub.n gene containing plasmids were transformed into E. coli BL21 (DE3) cells. A single bacterial colony was inoculated into 10 mL of TB media (1st primary culture) containing 50 mg/mL ampicillin and incubated at 37 C. for overnight growth at 150 rpm. 400 mL of TB medium supplemented with 50 mg/mL ampicillin was inoculated with the 1st primary culture in a 2-L flask and incubated at 37 C. for 4 hours at 200 rpm. The 2nd primary culture was inoculated into 500 mL of CircleGrow containing trace elements in a 2-L flask and incubated at 37 C. and 200 rpm. Bacterial cells were harvested by centrifugation and cell pellets were resuspended in PBS. Cells lysate was obtained by sonicating the resuspended sample on an ice bath for 5 minutes at 50% power (10 seconds on with 20-second intervals).
[0111] RBP[Dros].sub.n was purified by the ammonium sulfate precipitation and heating method as described in previous literatures with slight modifications. The sonicated sample was centrifuged at 16000 rpm for 30 minutes at 4 C. to remove insoluble cell debris and a PEI solution (0.5%) was added to the supernatant. Nucleic acid contaminants were separated by centrifuging at 16000 rpm for 15 minutes at 4 C. The clear soluble lysate was used for the purification of RBP[Dros]. The ammonium sulfate salt at final saturation of 30% was slowly added to the PEI-treated sample at 4 C. with stirring, mixed completely and kept for 20 minutes. Aggregated proteins were separated by centrifugation at 16000 rpm for 20 minutes at 4 C. and the pellet was resuspended in PBS. RBP[Dros].sub.n was separated with 20% s ammonium sulfate by centrifuging under the same condition as described above. The supernatant was discarded and the pellet was resuspended in PBS. The sample was dialyzed in excess PBS to remove the ammonium sulfate salt. A high-purity product was obtained using the thermal stability of RBP[Dros].sub.n and the sample was heated at 90 C. for 5 minutes with stirring which denatured the contaminated proteins. The RBP[Dros].sub.n was maintained in solubilized state even under the high temperature condition. The denatured proteins were removed by centrifuging at 13000 rpm for 20 minutes at room temperature. The pellet was discarded and pure RBP[Dros].sub.n existing in the supernatant was stored for further use.
[0112] For purification of the RBP[m-Dros].sub.n, the sonicated sample was centrifuged at 16000 rpm for 30 minutes at 4 C. The supernatant was discarded and the cell pellet was resuspended in 3-5 mL of PBS. The sample was heated at 65 C. for 20 minutes for complete solubilization and the heated sample was centrifuged at 16000 rpm for 15 minutes at room temperature to remove the contaminated proteins. The RBP[m-Dros].sub.n remained in the supernatant because of its solubility at high temperature. The supernatant was cooled at 4 C. for 30 minutes and then cooled to 20 C. for 5 minutes to trigger the phase transition of the RBP[m-Dros].sub.n which was visible due to increased turbidity. The aggregated proteins were separated by centrifugation at 16000 rpm for 10 minutes at 4 C. and the cell pellet was suspended in PBS at room temperature. The solubilization at high temperature and aggregation cycles at low temperature were continued for 3 more times to get purified proteins.
[0113] Purity and molecular weight were analyzed by SDS-PAGE for Coomassie-stained RBP[Dros].sub.n and copper-stained RBP[m-Dros].sub.n. The phase transition behavior of the RBP[m-Dros].sub.n was characterized by UV-visible spectrophotometry and dynamic light scattering (DLS). For the lower critical solution temperature, the 25 M sample solution was heated to 50 C. and then optical density at 350 nm (OD.sub.350) was measured from 50 C. to 10 C. as a function of temperature at a cooling rate of 1 C./min.
[0114] Through the agarose gel electrophoresis analysis, RBP[Dros].sub.n and RBP[m-Dros].sub.n gene libraries having various repeating units from 336 bp to 2766 bp were identified (
TABLE-US-00005 TABLE 5 Expected molecular weight of RBP[m-Dros].sub.n and RBP[Dros].sub.n multimerized by RDL RBP monoblock polypeptides MW (kDa) RBP[m-Dros].sub.3 8.48 RBP[m-Dros].sub.6 16.59 RBP[m-Dros].sub.12 32.81 RBP[m-Dros].sub.24 65.26 RBP[m-Dros].sub.30 81.48 RBP[Dros].sub.3 8.44 RBP[Dros].sub.6 16.50 RBP[Dros].sub.8 21.30 RBP[Dros].sub.12 32.63 RBP[Dros].sub.16 43.39 RBP[Dros].sub.24 64.90 RBP[Dros].sub.30 81.03
[0115]
Example 6. Synthesis and Expression of EBPP-RBPP Diblock Polypeptide Gene
[0116] As seen from
[0117] For expression of fusion proteins, the pET-21a(+) vector containing EBPP-RBP polypeptides was transformed into E. coli BL21(DE3) cells. A single colony was inoculated into 50 mL of CircleGrow media in 250-mL flasks containing 50 g/mL of ampicillin, and subsequently used to inoculate CircleGrow media in 2-L flasks. The flasks were incubated on a shaking incubator at 200 rpm and expression was induced by adding IPTG at a final concentration of 1 mM when the optical density (OD.sub.600) reached 1.0. The cultures were harvested after 18 hours of incubation and the fusion proteins were purified by ITC. The cell pellets were resuspended in PBS, and the cells lysate was obtained by sonicating the samples (VC-505, Sonic and Materials Inc., Danbury, Conn.) on an ice bath. The cells debris was separated by centrifugation at 16000 rpm for 15 minutes at 4 C. and the soluble lysate was transferred to a fresh tube. Then a PEI solution was added to a final concentration of 0.5% w/v and mixed well. Nucleic acid contaminants were separated by centrifuging at 16000 rpm for 15 minutes at 4 C. Sodium chloride was added at a final concentration of 3-4 M to the PEI-treated samples to trigger the phase transition of the fusion proteins. The aggregated fusion proteins were separated by centrifuging at 16000 rpm for 30 minutes at 40 C. The aggregated fusion proteins were resuspended in cold PBS, and the samples were centrifuged at 16000 rpm for 15 minutes at 4 C. to remove any remaining insoluble matter. This aggregation and resuspension process was repeated 4-5 times until an appropriate purity of the fusion proteins was obtained.
Example 7. Physicochemical Properties of EBPP-RBP Diblock Polypeptide
[0118]
TABLE-US-00006 TABLE 6 Expected molecular weight and transition temperature of EBPP-RBP diblock peptide having different block lengths EBPP-RBP diblock polypeptides MW (kDa) T.sub.tS EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.3 23.55 44.5 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.6 31.66 48.9 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.12 47.88 47.9 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.24 80.32 55.4 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.3 38.61 36.62 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6 46.72 33.21 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.12 62.94 31.49 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.24 95.39 28.00 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.3 23.50 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.6 31.57 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.12 47.70 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.24 79.96 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.3 38.57 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.6 46.63 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.12 62.76 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.24 95.03 N/A
[0119] The molecular weight of the diblock polypeptide varied from 23.55 to 95.03 kDa.
[0120] At this temperature, the EBPP[G.sub.1A.sub.3F.sub.2].sub.6 serves as a core and the RBP[m-Dros].sub.24 serves as a shell. Whereas the UCST of the monoblock is 18 C., the fusion of EBPP[G.sub.1A.sub.3F.sub.2].sub.6 and RBP[m-Dros].sub.24 resulted in increased UCST because the aggregated state is maintained until the thermal transition of the EBPP[G.sub.1A.sub.3F.sub.2].sub.6. For the EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.3, a micelle was not formed because the effect of the EBPP[G.sub.1A.sub.3F.sub.2].sub.6 was dominant throughout the temperature range due to the small molecular weight.
[0121]
Example 8. Synthesis and Expression of EBPP-RBP-EBPP Triblock Polypeptide Gene
[0122] EBPP-RBP-EBPP triblock peptides were synthesized in two steps. In the first step, a RBP-EBPP block copolymer was formed by inserting the RBP gene into an EBPP-containing plasmid. In the second step, the EBPP gene was inserted into the RBP-EBPP-containing plasmid. For vector preparation, 4 g of the plasmid was digested with 15 U of BseRI and 10 U of XbaI in FastDigest buffer for 30 minutes at 37 C. The 5 ends were dephosphorylated with 10 U of CIP in NEB 3 buffer for 1 hour at 37 C. The restricted vector was purified using the PCR purification kit. For insertion, the plasmid was doubly digested with 10 U of XbaI and 15 U of AcuI for 30 minutes at 37 C. The digested product was separated by agarose gel electrophoresis and purified using the PCR purification kit. Ligation was carried out by incubating 90 pmol of the purified insert and 30 pmol of the linearized vector in T4 DNA ligase buffer containing 1 U of T4 DNA ligase at 16 C. for 30 minutes. E. coli Top 10 competent cells were transformed with the ligated product and then spread on SOC plates supplemented with 50 g/mL of ampicillin. Triblock polypeptides with different EBP lengths and RBP genes were synthesized and all block lengths were checked by agarose gel electrophoresis after restriction by XbaI and AcuI and further confirmed by DNA sequencing. Then, the expression of fusion proteins was conducted in the same manner as in Example 6.
Example 9. Physicochemical Properties of EBPP-RBP-EBPP Triblock Polypeptide
[0123]
[0124] Under physiological conditions and above the T.sub.t, the hydrophobic EBPP block self-assembled with the hydrophilic RBP middle block containing the tyrosine residues to form a physically crosslinked hydrogel. The mechanical properties of the physically crosslinked hydrogel was enhanced by the chemical crosslinkages of the tyrosine residues on the RBP block. The expected molecular weight and transition temperature (T.sub.t) depending on the lengths of the hydrophobic block and the RBP[m-Dros].sub.n when EBPP[G.sub.1A.sub.3F.sub.2].sub.12 or EBPP[G.sub.1A.sub.3F.sub.2].sub.24 is fused with RBP[m-Dros].sub.n of various lengths are given in Table 7. In addition, in order to confirm the effect of physical crosslinking, EBPP or EBPPI libraries differing only in the first amino acid residue of the pentapeptide repeating unit (Val or Ile) were fused with the same RBP[m-Dros] block.
TABLE-US-00007 TABLE 7 Expected molecular weight and transition temperature of EBPP(I)- RBP-EBPP(I) triblock peptides having different block lengths EBPP-RBP-EBPP triblock polypeptides MW (kDa) T.sub.tS EBPPI[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPPI[G.sub.1A.sub.3F.sub.2].sub.12 78.9 14.5 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 76.8 29.74 EBPP[G.sub.1A.sub.3F.sub.2].sub.24-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.24 137.1 25.59 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.12-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 93.1 27.86 EBPP[G.sub.1A.sub.3F.sub.2].sub.24-RBP[m-Dros].sub.12-EBPP[G.sub.1A.sub.3F.sub.2].sub.24 153.3 23.10
[0125] The transition temperature was decreased as the EBPP[G.sub.1A.sub.3F.sub.2] block length was increased. In particular, the triblock polypeptides having EBPPI libraries showed much lower transition temperatures (T.sub.t) than the triblock polypeptides of the same block lengths having EBPP libraries. That is to say, the LOST of EBPPI[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPPI[G.sub.1A.sub.3F.sub.2].sub.12 was much lower than that of the EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 triblock polypeptide of the same block length but having EBPP library. Such a significant decrease in T.sub.t is due to the substitution of Val in the first position of the pentapeptide repeat with the relatively more hydrophobic Ile.
[0126]
[0127]
[0128]
Example 10. Rheological Measurement of EBPP-RBP-EBPP Triblock Polypeptide
[0129] Various concentrations of EBPP-RBP-EBPP polypeptide solutions were prepared using phosphate-buffered saline (PBS, pH 7.4) and subjected to dynamic-shear rheological test to measure the elastic modulus (G), loss modulus (G), complex shear modulus (G*), complex viscosity (*) and loss angle () as functions of temperature and frequency. The G characterizes the elastic behavior of a material while the G characterizes its viscous behavior. G* and * represent the frequency-dependent stiffness and the frequency-dependent viscous drag of a viscoelastic liquid or solid, respectively. The loss angle () is a relative measure of viscous to elastic properties (Newtonian viscous fluid: =90; elastic solid: =0). A metal solvent trap under fully hydrating conditions was used to prevent solvent evaporation over temperatures ranging from 10 C. to 40 C. Dynamic frequency sweep measurements were performed in the linear viscoelastic regime at different temperatures, as confirmed by independent strain sweep tests (strain sweep range: 0.2-20%, angular frequency: 0.1, 1.0 or 10 rad/s). The angular frequency ranged from 1.0 to 100 rad/s, both at 10 C. (below T.sub.t) and 40 C. (above T.sub.t) for the frequency sweep tests. The temperature sweep tests were executed with 2% strain at 1 rad/s over a temperature range of 10 C. to 45 C. with one-minute duration per degree for forward heating and reverse cooling measurements to examine the reversibility of their rheological and mechanical properties. All measurements were made 3 times to ensure reproducibility.
[0130]
[0131]
[0132] The present invention has been described in detail with reference to specific embodiments thereof. However, it will be appreciated by those skilled in the art that various changes and modifications may be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.